tirzepatide cvot results Efficacy and safety of in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial 🫀 EASD 2025: Tirzepatide (SURPASS-CVOT)

Superior Bioavailability Through Liquid Format This is a practical advantage thats easy to overlook but critical in real-world use

Studies have shown that this patient population reaches the anaerobic threshold much more quickly, meaning that they would reach a level of oxygen consumption much more rapidly, leading to lactic acid buildup

Moreover, the sudden withdrawal of nicotine can cause palpitations as your body adjusts to the absence of the substance

GLP Sources was created to provide a clear, source-linked reference explaining how GLP-1 medications work, how semaglutide and tirzepatide differ, what real clinical trials show about weight loss, and what safety considerations patients should understand before discussing treatment with a licensed clinician